KDM4B Recombinant Monoclonal Antibody

說明書

中文名稱：

KDM4B Recombinant Monoclonal Antibody
貨號：

CSB-RA889767A0HU
規格：

￥1320
圖片：
IHC image of CSB-RA889767A0HU diluted at 1:100 and staining in paraffin-embedded human thyroid tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.

Immunofluorescence staining of U-251MG cell with CSB-RA889767A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Overlay Peak curve showing PC-3 cells stained with CSB-RA889767A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for?10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

O94953
基因名：

KDM4B
別名：

Lysine-specific demethylase 4B (EC 1.14.11.-) (JmjC domain-containing histone demethylation protein 3B) (Jumonji domain-containing protein 2B), KDM4B, JHDM3B JMJD2B KIAA0876
反應種屬：

Human
免疫原：

A synthesized peptide from human KDM4B protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

1F9
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, IF, FC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27', H3 'Lys-36' nor H4 'Lys-20'. Only able to demethylate trimethylated H3 'Lys-9', with a weaker activity than KDM4A, KDM4C and KDM4D. Demethylation of Lys residue generates formaldehyde and succinate.
基因功能參考文獻：
1. findings illustrate the significance of CREB-KDM4B-STAT3 signaling cascade in DNA damage response, and highlight that KDM4B may potentially be a novel oncotarget for colorectal cancer radiotherapy. PMID: 29633065
2. p-ERK-mediated phosphorylation and stabilization of JMJD2B during glucose deprivation contributes to its role in glucose uptake and cell viability, which may be modulated through epigenetically upregulation of GLUT1 in colon cancer cells. PMID: 28945223
3. KDM4B may play an important role in mitochondrial apoptosis and represent a potential therapeutic cancer target in colorectal cancer PMID: 27506941
4. High KDM4B expression is associated with Neuroblastomas. PMID: 28684529
5. This is the first demonstration that a Jumonji-domain histone demethylase regulates cellular processes required for peritoneal dissemination of cancer cells, one of the predominant factors affecting prognosis of EOC. The pathways regulated by KDM4B may present novel opportunities to develop combinatorial therapies to improve existing therapies for EOC patients. PMID: 27869162
6. identification of JMJD2B/KDM4B as a p53-inducible gene in response to DNA damage. PMID: 28073943
7. KDM4B and KDM4D expression may associate with an aggressive subtype of classical Hodgkin lymphoma and be linked with radioresistance PMID: 27630312
8. KDM4B is a key mediator in epithelial-mesenchymal transition process, and may serve as an important prognostic marker and therapeutic target for the metastatic progression of human pancreatic cancer PMID: 26511091
9. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. CONCLUSION: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma PMID: 27630338
10. upon TGF-beta stimulation, KDM4B was recruited to the SOX9 promoter, removed the silencing H3K9me3 marks, and activated the transcription of SOX9. PMID: 26485430
11. High KDM4B expression is associated with endometrial cancer progression. PMID: 26397136
12. JMJD2B and JMJD2C play an important role in the pathology of osteosarcoma via the up-regulation of FGF2. PMID: 25636512
13. results reveal that JMJD2B is dramatically upregulated in hepatocellular carcinoma, making it a potential diagnostic marker for the further development of HCC treatment therapies PMID: 25533242
14. Functional studies demonstrated that KDM4B regulates the Myc pathway. N-Myc was found to physically interact with and recruit KDM4B. KDM4B was found to regulate neuroblastoma cell proliferation and differentiation in vitro and xenograft growth in vivo. PMID: 25925418
15. Data indicate that miR-491-5p plays a tumor suppressor role in the development and progression of breast cancer via direct targeting the 3'UTR of JMJD2B mRNA. PMID: 25725194
16. Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer. PMID: 24957706
17. KDM4B was upregulated in colon and rectal adenocarcinomas and required for efficient growth and clonogenic activity of human HT-29 colon cancer cells. PMID: 24481461
18. A novel function of JMJD2B in promoting epithelial-mesenchymal transition and gastric cancer invasion and metastasis. PMID: 24077348
19. Results suggest that by regulating JMJD2b and SUV39H1 expression, p53 not only controls transcription but also promotes HC relaxation to accelerate a rate-limiting step in the repair of complex genomes. PMID: 23376847
20. Jumonji domain-containing protein 2B has an essential role in cancer cell survival and tumor growth via DNA damage response mediation, which STAT3 partially regulates. PMID: 24473398
21. novel pathway by which Hsp90 activity alters the histone code via regulation of KDM4B stability. PMID: 23589305
22. JMJD2B may play a central role in gastric cancer cell growth and might constitute a novel therapeutic target to overcome hypoxia-induced radio-resistance, thereby improving the efficiency of radiation therapy. PMID: 23046878
23. JMJD2B interacts with ERalpha and components of the SWI/SNF-B chromatin remodeling complex. JMJD2B is recruited to ERalpha target sites, demethylates H3K9me3 and facilitates transcription of ER responsive genes including MYB, MYC and CCND1. PMID: 21445275
24. The histone demethylases KDM4B and KDM6B play critical roles in osteogenic commitment of mesenchymal stem/stromal cells. PMID: 22770241
25. showed that JMJD2B was overexpressed in colorectal cancer tissues and positively correlated with expression of the hypoxic marker carbonic anhydrase 9 PMID: 22745382
26. High JMJD2B is associated with bladder and lung carcinogenesis through positive regulation of cyclin-dependent kinase 6. PMID: 21930796
27. JMJD2B is required for sustained proliferation and survival of tumor cells in vitro and in vivo, and its aberrant expression may contribute to the pathogenesis of gastric cancer. PMID: 22133676
28. knockdown of JMJD2B severely impairs estrogen-induced cell proliferation and the tumor formation capacity of breast cancer cells PMID: 21445275
29. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. PMID: 21502505
30. Histone demethylase JMJD2B is regulated by both ERalpha and HIF-1alpha, drives breast cancer cell proliferation in normoxia and hypoxia, and epigenetically regulates the expression of cell cycle genes. PMID: 20682797
31. Two GATA-binding sites within intron 6 of human JMJD2B gene were conserved in mouse Jmjd2b gene. PMID: 17611647
32. Results show that many genes regulated by hypoxia and HIF-1alpha show patterns of induction with JMJD (Jumonji-domain containing)1A and JMJD2B demonstrating robust, and JMJD2C more modest, up-regulation by hypoxia. PMID: 18713068
33. histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF PMID: 18984585
顯示更多

收起更多
亞細胞定位：

Nucleus.
蛋白家族：

JHDM3 histone demethylase family
數據庫鏈接：

HGNC: 29136

OMIM: 609765

KEGG: hsa:23030

STRING: 9606.ENSP00000159111

UniGene: Hs.654816

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human